Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling.

Identification of Drug-Drug Interactions (DDIs) is a significant challenge during drug development and clinical practice. DDIs are responsible for many adverse drug effects (ADEs), decreasing patient quality of life and causing higher care expenses. DDIs are not systematically evaluated in pre-clini...

Full description

Bibliographic Details
Main Authors: Santiago Vilar, Tal Lorberbaum, George Hripcsak, Nicholas P Tatonetti
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4466327?pdf=render
id doaj-861dcd0b1fdb4806b13130a99765145a
record_format Article
spelling doaj-861dcd0b1fdb4806b13130a99765145a2020-11-25T01:18:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01106e012997410.1371/journal.pone.0129974Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling.Santiago VilarTal LorberbaumGeorge HripcsakNicholas P TatonettiIdentification of Drug-Drug Interactions (DDIs) is a significant challenge during drug development and clinical practice. DDIs are responsible for many adverse drug effects (ADEs), decreasing patient quality of life and causing higher care expenses. DDIs are not systematically evaluated in pre-clinical or clinical trials and so the FDA U. S. Food and Drug Administration relies on post-marketing surveillance to monitor patient safety. However, existing pharmacovigilance algorithms show poor performance for detecting DDIs exhibiting prohibitively high false positive rates. Alternatively, methods based on chemical structure and pharmacological similarity have shown promise in adverse drug event detection. We hypothesize that the use of chemical biology data in a post hoc analysis of pharmacovigilance results will significantly improve the detection of dangerous interactions. Our model integrates a reference standard of DDIs known to cause arrhythmias with drug similarity data. To compare similarity between drugs we used chemical structure (both 2D and 3D molecular structure), adverse drug side effects, chemogenomic targets, drug indication classes, and known drug-drug interactions. We evaluated the method on external reference standards. Our results showed an enhancement of sensitivity, specificity and precision in different top positions with the use of similarity measures to rank the candidates extracted from pharmacovigilance data. For the top 100 DDI candidates, similarity-based modeling yielded close to twofold precision enhancement compared to the proportional reporting ratio (PRR). Moreover, the method helps in the DDI decision making through the identification of the DDI in the reference standard that generated the candidate.http://europepmc.org/articles/PMC4466327?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Santiago Vilar
Tal Lorberbaum
George Hripcsak
Nicholas P Tatonetti
spellingShingle Santiago Vilar
Tal Lorberbaum
George Hripcsak
Nicholas P Tatonetti
Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling.
PLoS ONE
author_facet Santiago Vilar
Tal Lorberbaum
George Hripcsak
Nicholas P Tatonetti
author_sort Santiago Vilar
title Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling.
title_short Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling.
title_full Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling.
title_fullStr Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling.
title_full_unstemmed Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling.
title_sort improving detection of arrhythmia drug-drug interactions in pharmacovigilance data through the implementation of similarity-based modeling.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Identification of Drug-Drug Interactions (DDIs) is a significant challenge during drug development and clinical practice. DDIs are responsible for many adverse drug effects (ADEs), decreasing patient quality of life and causing higher care expenses. DDIs are not systematically evaluated in pre-clinical or clinical trials and so the FDA U. S. Food and Drug Administration relies on post-marketing surveillance to monitor patient safety. However, existing pharmacovigilance algorithms show poor performance for detecting DDIs exhibiting prohibitively high false positive rates. Alternatively, methods based on chemical structure and pharmacological similarity have shown promise in adverse drug event detection. We hypothesize that the use of chemical biology data in a post hoc analysis of pharmacovigilance results will significantly improve the detection of dangerous interactions. Our model integrates a reference standard of DDIs known to cause arrhythmias with drug similarity data. To compare similarity between drugs we used chemical structure (both 2D and 3D molecular structure), adverse drug side effects, chemogenomic targets, drug indication classes, and known drug-drug interactions. We evaluated the method on external reference standards. Our results showed an enhancement of sensitivity, specificity and precision in different top positions with the use of similarity measures to rank the candidates extracted from pharmacovigilance data. For the top 100 DDI candidates, similarity-based modeling yielded close to twofold precision enhancement compared to the proportional reporting ratio (PRR). Moreover, the method helps in the DDI decision making through the identification of the DDI in the reference standard that generated the candidate.
url http://europepmc.org/articles/PMC4466327?pdf=render
work_keys_str_mv AT santiagovilar improvingdetectionofarrhythmiadrugdruginteractionsinpharmacovigilancedatathroughtheimplementationofsimilaritybasedmodeling
AT tallorberbaum improvingdetectionofarrhythmiadrugdruginteractionsinpharmacovigilancedatathroughtheimplementationofsimilaritybasedmodeling
AT georgehripcsak improvingdetectionofarrhythmiadrugdruginteractionsinpharmacovigilancedatathroughtheimplementationofsimilaritybasedmodeling
AT nicholasptatonetti improvingdetectionofarrhythmiadrugdruginteractionsinpharmacovigilancedatathroughtheimplementationofsimilaritybasedmodeling
_version_ 1725140461860945920